Date: 2015-07-14
Type of information: Initiation of patient enrollment
phase: 1
Announcement: initiation of patient enrollment
Company: Blaze Biosciences (USA - WA)
Product: BLZ-100 - chlorotoxin conjugated to indocyanine green dye
Action
mechanism: peptide. BLZ-100 is the first product candidate from Blaze’s Tumor Paint platform and consists of an optimized peptide, which binds and internalizes into cancer cells, and a fluorescent dye, which emits light in the near-infrared range. Tumor Paint products are designed to provide real-time, high-resolution intraoperative visualization of cancer cells, enabling more precise, complete resection of cancer throughout surgery. Preclinical utility of Tumor Paint technology has been demonstrated in a wide range of cancer types, including brain, lung, breast, prostate, and colorectal.
Disease: solid tumors
Therapeutic area: Cancer - Oncology
Country: USA
Trial
details: This phase 1 study is an exploratory study of the safety and ex vivo fluorescence of BLZ-100 administered by intravenous injection in adult subjects with solid tumors undergoing surgery. (NCT02496065)
Latest
news: * On July 14, 2015, Blaze Bioscience announced expansion of its Phase 1 program into multiple additional tumor types. The study, which is open for enrollment, is titled “A Phase 1 exploratory study of the safety and ex vivo fluorescence of BLZ-100 administered by intravenous injection in adult subjects with solid tumors undergoing surgery,” and will enroll up to thirty (30) patients. The study is
currently active at Overlake Medical Center in Bellevue, WA under the direction of principal investigator Kristi Harrington, M.D., Ph.D.
